Oludamilola Akinmolayemi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oludamilola Akinmolayemi has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Gregg Whitney Stone
Icahn School of Medicine at Mount Sinai , New York, NY
3 shared publications - Anand Rohatgi
University of Texas Southwestern Medical Center
2 shared publications - Mahesh V. Madhavan
Structural Heart and Valve Center, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, New York, New York, USA
2 shared publications - Samin K. Sharma
Icahn School of Medicine at Mount Sinai New York New York USA
2 shared publications Adrija Mehta
RUHS Coll Med Sci, Jaipur, India
1 shared publicationAkarsh Sharma
1 shared publication
Latest Publications
- Open Access
- 8 June 2026
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (11) , 1509-1517.e13
Optimal medical therapy in patients with chronic coronary syndrome undergoing PCI: Temporal trends and outcomes
- 8 June 2026
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (11) , 1509-1517.e13
Open AccessOptimal medical therapy in patients with chronic coronary syndrome undergoing PCI: Temporal trends and outcomes
- Open Access
- 16 April 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
Patient Selection for Supersaturated Oxygen Therapy in Anterior STEMI
- 16 April 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
Open AccessPatient Selection for Supersaturated Oxygen Therapy in Anterior STEMI
- Open Access
- 30 December 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (2)
Right-Sided Extravalvular Damage: An Overlooked Driver of Risk Model Failure in Low-Flow, Low-Gradient Aortic Stenosis
- 30 December 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (2)
Open AccessRight-Sided Extravalvular Damage: An Overlooked Driver of Risk Model Failure in Low-Flow, Low-Gradient Aortic Stenosis
- Open Access
- 30 October 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (3)
Impact of Race and Ethnicity on Outcomes After Mitral Transcatheter Edge-to-Edge Repair: Analysis From the COAPT Trial
- 30 October 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (3)
Open AccessImpact of Race and Ethnicity on Outcomes After Mitral Transcatheter Edge-to-Edge Repair: Analysis From the COAPT Trial
- 23 October 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (8) , 2241-2248
Racial Disparities in Incident and Recurrent Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis
Most prior studies of cardiovascular (CVD) events have focused on incident events. We analyzed differences by race/ethnicity in incident and recurrent CVD events in the Multi-Ethnic Study of Atherosclerosis from baseline in 2000-2002 through 2019 using joint and multivariable adjusted Cox proportional hazards modeling. Among 6,814 men and women aged 45-85 years without known CVD at enrollment, during median follow up of 17.7 years, 1206 incident and 695 recurrent CVD events were observed; 891 individuals with a non-fatal incident event were at risk for recurrent events. Rates of combined incident and recurrent CVD events among Black, White, Chinese, and Hispanic participants were 16.8, 18.6, 13.3, and 19.3 per 1000 person-years, respectively. First recurrent CVD event rates in Black, White, Chinese, and Hispanic participants were 87.7, 68.7, 78.1, and 80.7 per 1000 person-years, respectively. Revascularization rates were lower in Black versus White participants (3.8 vs 6.4 per 1000 person-years, p<0.0001). Adjusted hazard for CVD mortality was higher for Black vs. White participants (hazard ratio 1.85; 95% CI: 1.03, 3.29). In this multi-ethnic cohort, Black participants had a lower or similar rate of incident and recurrent CVD events, lower rate of revascularization, and higher rate of fatal CVD compared to White participants.
- 23 October 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (8) , 2241-2248
Racial Disparities in Incident and Recurrent Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis
Most prior studies of cardiovascular (CVD) events have focused on incident events. We analyzed differences by race/ethnicity in incident and recurrent CVD events in the Multi-Ethnic Study of Atherosclerosis from baseline in 2000-2002 through 2019 using joint and multivariable adjusted Cox proportional hazards modeling. Among 6,814 men and women aged 45-85 years without known CVD at enrollment, during median follow up of 17.7 years, 1206 incident and 695 recurrent CVD events were observed; 891 individuals with a non-fatal incident event were at risk for recurrent events. Rates of combined incident and recurrent CVD events among Black, White, Chinese, and Hispanic participants were 16.8, 18.6, 13.3, and 19.3 per 1000 person-years, respectively. First recurrent CVD event rates in Black, White, Chinese, and Hispanic participants were 87.7, 68.7, 78.1, and 80.7 per 1000 person-years, respectively. Revascularization rates were lower in Black versus White participants (3.8 vs 6.4 per 1000 person-years, p<0.0001). Adjusted hazard for CVD mortality was higher for Black vs. White participants (hazard ratio 1.85; 95% CI: 1.03, 3.29). In this multi-ethnic cohort, Black participants had a lower or similar rate of incident and recurrent CVD events, lower rate of revascularization, and higher rate of fatal CVD compared to White participants.
- 23 May 2023
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 36 (9)
Severe Functional Mitral Regurgitation and Cardiogenic Shock After Transcatheter Aortic Valve Replacement
An 83-year-old woman with symptomatic severe aortic stenosis was referred for transcatheter aortic valve replacement. Diagnostic left heart catheterization documented diffuse 3-vessel coronary artery disease.
- 23 May 2023
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 36 (9)
Severe Functional Mitral Regurgitation and Cardiogenic Shock After Transcatheter Aortic Valve Replacement
An 83-year-old woman with symptomatic severe aortic stenosis was referred for transcatheter aortic valve replacement. Diagnostic left heart catheterization documented diffuse 3-vessel coronary artery disease.
- Open Access
- 21 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0257574
Cholesterol efflux capacity and its association with prevalent metabolic syndrome in a multi-ethnic population (Dallas Heart Study)
Metabolic syndrome (MetS) is characterized by adiposity and atherogenic dyslipidemia consisting of elevated triglyceride and decreased high density lipoprotein cholesterol (HDL-C) levels however, cholesterol concentration alone does not reflect HDL functionality. Cholesterol efflux capacity (CEC) captures a key anti-atherosclerotic function of HDL; studies linking CEC to MetS have yielded inconsistent findings and lacked racial/ethnic diversity. The aim of this study was to evaluate the association between CEC and MetS in a large multi-ethnic population utilizing two different CEC assays interrogating overlapping but distinct reverse cholesterol transport pathways. A cross-sectional study was performed using the Dallas Heart Study cohort and cholesterol efflux was measured with radiolabeled and fluorescent cholesterol assays. The relationship between CEC and MetS was assessed using multivariable regression analyses. A total of 2241 participants were included (mean age was 50 years; 38% men and 53% Blacks). CEC was independently and inversely associated with MetS irrespective of efflux assay (CEC-radiolabeled, adjusted OR 0·71 [95% CI 0·65–0·80]. CEC-fluorescent, adjusted OR 0·85 [95% CI 0·77–0·94]). Both CEC measures were inversely associated with waist circumference and directly associated with HDL-C but not with other MetS components. There was an interaction by sex but not by race such that the inverse associations between CEC and MetS were somewhat attenuated in men (OR 0·86, 95%CI 0·74–1·01). In this large multi-ethnic cohort, impaired CEC is linked to MetS irrespective of efflux assay and race/ethnicity but less so among men. Future studies are needed to assess whether CEC mediates the atherosclerotic cardiovascular disease risk of MetS.
- 21 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0257574
Open AccessCholesterol efflux capacity and its association with prevalent metabolic syndrome in a multi-ethnic population (Dallas Heart Study)
Metabolic syndrome (MetS) is characterized by adiposity and atherogenic dyslipidemia consisting of elevated triglyceride and decreased high density lipoprotein cholesterol (HDL-C) levels however, cholesterol concentration alone does not reflect HDL functionality. Cholesterol efflux capacity (CEC) captures a key anti-atherosclerotic function of HDL; studies linking CEC to MetS have yielded inconsistent findings and lacked racial/ethnic diversity. The aim of this study was to evaluate the association between CEC and MetS in a large multi-ethnic population utilizing two different CEC assays interrogating overlapping but distinct reverse cholesterol transport pathways. A cross-sectional study was performed using the Dallas Heart Study cohort and cholesterol efflux was measured with radiolabeled and fluorescent cholesterol assays. The relationship between CEC and MetS was assessed using multivariable regression analyses. A total of 2241 participants were included (mean age was 50 years; 38% men and 53% Blacks). CEC was independently and inversely associated with MetS irrespective of efflux assay (CEC-radiolabeled, adjusted OR 0·71 [95% CI 0·65–0·80]. CEC-fluorescent, adjusted OR 0·85 [95% CI 0·77–0·94]). Both CEC measures were inversely associated with waist circumference and directly associated with HDL-C but not with other MetS components. There was an interaction by sex but not by race such that the inverse associations between CEC and MetS were somewhat attenuated in men (OR 0·86, 95%CI 0·74–1·01). In this large multi-ethnic cohort, impaired CEC is linked to MetS irrespective of efflux assay and race/ethnicity but less so among men. Future studies are needed to assess whether CEC mediates the atherosclerotic cardiovascular disease risk of MetS.
- Open Access
- 3 December 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (12) , 2137
Impaired HDL Metabolism Links GlycA, A Novel Inflammatory Marker, with Incident Cardiovascular Events
High-density lipoproteins (HDL) exert anti-atherosclerotic effects via reverse cholesterol transport, yet this salutary property is impaired in the setting of inflammation. GlycA, a novel integrated glycosylation marker of five acute phase reactants, is linked to cardiovascular (CV) events. We assessed the hypothesis that GlycA is associated with measures of impaired HDL function and that dysfunctional HDL may contribute to the association between GlycA and incident CV events. Baseline measurements of HDL cholesterol (HDL-C), HDL particle concentration (HDL-P), apoliprotein A1 (Apo A1), cholesterol efflux capacity, GlycA and high-sensitivity C-reactive protein (hs-CRP) were obtained from the Dallas Heart Study, a multi-ethnic cohort of 2643 adults (median 43 years old; 56% women, 50% black) without cardiovascular disease (CVD). GlycA was derived from nuclear magnetic resonance imaging. Participants were followed for first nonfatal MI, nonfatal stroke, coronary revascularization, or CV death over a median of 12.4 years (n = 197). The correlation between GlycA and hs-CRP was 0.58 (p < 0.0001). In multivariate models with HDL-C, GlycA was directly associated with HDL-P and Apo A1 and inversely associated with cholesterol efflux (standardized beta estimates: 0.08, 0.29, -0.06, respectively; all p ≤ 0.0004) GlycA was directly associated with incident CV events (adjusted hazard ratio (HR) for Q4 vs. Q1: 3.33, 95% confidence interval (CI) 1.99, 5.57). Adjustment for cholesterol efflux mildly attenuated this association (HR for Q4 vs. Q1: 3.00, 95% CI 1.75 to 5.13). In a multi-ethnic cohort, worsening inflammation, as reflected by higher GlycA levels, is associated with higher HDL-P and lower cholesterol efflux. Impaired cholesterol efflux likely explains some of the association between GlycA and incident CV events. Further studies are warranted to investigate the impact of inflammation on HDL function and CV disease.
- 3 December 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (12) , 2137
Open AccessImpaired HDL Metabolism Links GlycA, A Novel Inflammatory Marker, with Incident Cardiovascular Events
High-density lipoproteins (HDL) exert anti-atherosclerotic effects via reverse cholesterol transport, yet this salutary property is impaired in the setting of inflammation. GlycA, a novel integrated glycosylation marker of five acute phase reactants, is linked to cardiovascular (CV) events. We assessed the hypothesis that GlycA is associated with measures of impaired HDL function and that dysfunctional HDL may contribute to the association between GlycA and incident CV events. Baseline measurements of HDL cholesterol (HDL-C), HDL particle concentration (HDL-P), apoliprotein A1 (Apo A1), cholesterol efflux capacity, GlycA and high-sensitivity C-reactive protein (hs-CRP) were obtained from the Dallas Heart Study, a multi-ethnic cohort of 2643 adults (median 43 years old; 56% women, 50% black) without cardiovascular disease (CVD). GlycA was derived from nuclear magnetic resonance imaging. Participants were followed for first nonfatal MI, nonfatal stroke, coronary revascularization, or CV death over a median of 12.4 years (n = 197). The correlation between GlycA and hs-CRP was 0.58 (p < 0.0001). In multivariate models with HDL-C, GlycA was directly associated with HDL-P and Apo A1 and inversely associated with cholesterol efflux (standardized beta estimates: 0.08, 0.29, -0.06, respectively; all p ≤ 0.0004) GlycA was directly associated with incident CV events (adjusted hazard ratio (HR) for Q4 vs. Q1: 3.33, 95% confidence interval (CI) 1.99, 5.57). Adjustment for cholesterol efflux mildly attenuated this association (HR for Q4 vs. Q1: 3.00, 95% CI 1.75 to 5.13). In a multi-ethnic cohort, worsening inflammation, as reflected by higher GlycA levels, is associated with higher HDL-P and lower cholesterol efflux. Impaired cholesterol efflux likely explains some of the association between GlycA and incident CV events. Further studies are warranted to investigate the impact of inflammation on HDL function and CV disease.